¡¡
¡¡ÕªÒª£º×éµ°°×È¥ÒÒõ£»¯Ã¸ £¨HDAC£© ¾ßÓжàÖÖ¹¦ÄÜ£¬ ¶øHDAC3¶ÔѪ¹ÜÄÚÆ¤Ï¸°û¼°Ö×ÁöѪ¹ÜÉú³É¾ßÓÐÒ»¶¨µÄÓ°Ïì¡£±¾ÎÄ×ÛÊöHDAC3¶ÔѪ¹ÜÄÚÆ¤Ï¸°ûµÄ×÷Ó㬠²ûÃ÷HDAC3¼°ÆäÒÖÖÆ¼ÁÓë¶àÖÖ¼²²¡µÄ¹ØÏµ¡£
¡¡¡¡
¡¡¡¡
¹Ø¼ü´Ê£º×éµ°°×È¥ÒÒõ£»¯Ã¸£» Ѫ¹ÜÄÚÆ¤Ï¸°û£» ÒÖÖÆ¼Á£»
¡¡¡¡
¡¡¡¡Ñª¹ÜÄÚÆ¤Ï¸°ûÊÇÖ¸¸²×ÅÓÚѪ¹ÜÄÚ±íÃæµÄµ¥²ã±âƽ»ò¶à½ÇÐÎϸ°û£¬ Ëü¹ã·ºµØ·Ö²¼ÔÚÌåÄÚ£¬ ÄÜÓÐЧά³Ö»úÌåÕý³£µÄÉúÀí¹¦ÄÜ¡£³öÏÖËðÉË»ò¹¦ÄÜÎÉÂÒµÄѪ¹ÜÄÚÆ¤Ï¸°ûÄܹ»ÖÂʹ¶àÖÖ¼²²¡µÄ·¢Éú£¬ Èç¸ßѪѹ¡¢¹ÚÐIJ¡ºÍÌÇÄò²¡µÈ¼²²¡¡£×éµ°°×È¥ÒÒõ£»¯Ã¸ £¨histone deacetylases, HDACs£© ÓµÓд߻¯×éµ°°×È¥ÒÒõ£»¯µÄ¹¦Ó㬠¸Ã×÷ÓÃÄÜÓÐЧµ÷¿ØÑª¹ÜÄÚÆ¤Ï¸°ûµÄÔöÖ³¡£ÔÚHDACsÖÐHDAC3ÓëѪ¹ÜµÄÉú³ÉÃÜÇÐÏà¹Ø[1-2].±¾ÎľÍHDAC3ÓëѪ¹ÜÄÚÆ¤Ï¸°ûµÄ¹ØÏµ½øÐÐ×ÛÊö¡£
¡¡¡¡
¡¡¡¡
1 ×éµ°°×È¥ÒÒõ£»¯Ã¸
¡¡¡¡
¡¡¡¡HDACsÊÇÒ»ÀàпÀë×ÓÒÀÀµÐÔ½ðÊôµ°°×ø£¬ ¾ßÓÐÖÐÖ¹»ùÒòת¼ºÍ´Ù½ø×éµ°°×È¥ÒÒõ£»¯µÄ¹¦Ó㬠¸ù¾Ý½á¹¹ºÍ¹¦Äܲ»Í¬½«Æä·ÖΪ4Àà¡£¢ñÀàHDACsº¬HDAC1¡¢HDAC2¡¢HDAC3ºÍHDAC8, ËüÃÇÖ÷Òª¼¯ÖÐÉ¢²¼ÔÚϸ°ûºËÉÏ¡£¢òÀàHDACs·ÖΪaÀàºÍbÀ࣬ ¢òa¹²ÓÐHDAC4¡¢HDAC5¡¢HDAC7ºÍHDAC9ËĸöÑÇÐÍ£¬ ¢òbÀàÖеÄHDAC6ºÍHDAC10´ó²¿·Ö´æÔÚÓÚϸ°ûÖÊ¡£¢óÀàHDACs £¨ÓÖÃûsirtuins£© ÊǽÍĸsir2µÄÀàËÆµ°°×¡£¢ôÀà¼Ò×åÖÐÖ»ÓÐHDAC11Ò»ÖÖÒÒõ£»¯Ã¸¡£
¡¡¡¡
¡¡¡¡HDAC1·¢»ÓÉúÀí»îÐÔÖ÷ÒªÊÇͨ¹ýÓëHDAC2¡¢Sin3¡¢Co-RESTºÍDNA½áºÏµ°°× £¨YY1µ°°×£© µÈ½áºÏ[3].HDAC3ÊôÓÚÒ»ÖÖÄܹ»ÒÖÖÆ»ùÒòת¼µÄºËø¡£HDAC8ÒÔµ¥Ìåµ°°×µÄģʽÔÚÌåÄÚ³ÖÓУ¬ ²ÎÓëµ÷½Ú¼¡Ï¸°ûµÄÉìËõÐÔ¡£HDAC5ºÍHDAC9Ö÷Òª·ÖÉ¢ÔÚ¼¡Èâ×éÖ¯¡¢´óÄÔºÍÐÄÔàÖС£HDAC7¼¯Öзֲ¼ÔÚÐØÏÙºÍÄÚÆ¤Ï¸°ûÖÐ[4].¢òaÀàHDACsÔÚÖÚ¶à×éÖ¯·¢ÓýºÍ¼²²¡ÖÐÆðµ½ÖØÒªµÄ×÷Óá£HDAC6ºÍHDAC10Ö÷ÒªÊÇͨ¹ýÓëÆäËûHDACsÑÇÐÍÏ໥×÷Ó÷¢»Óе÷¹¦ÄÜ¡£¢òaºÍ¢òb¼ä×îÖØÒªµÄÇø±ðµãÔÚÓÚÓë14-3-3µ°°×µÄN¶Ë½áºÏλµãºÍ¼¡Ï¸°ûÔöÇ¿Òò×Ó2µÄÁ¬½Ó¡£sirtuinsͨ¹ýNAD+Ë®½â×éµ°°×µÄÀµ°±Ëá²Ð»ù²àÁ´Ä©¶Ë°±»ùµÄÒÒõ£»ùÉú³ÉÑÌõ£°·ºÍO-ÒÒõ£»ù-ADPºËÌÇ£¬ ²úÎï¿Éʹ»ùÒò³ÁĬ×îÖÕÑÓ³¤»úÌåÊÙÃü¡£HDAC11[5]µÄ½á¹¹Ó벿·Ö¢ñÀàHDACsµÄÏàËÆ£¬ µ«Æä¹¦ÄÜÉв»È·¶¨¡£
¡¡¡¡
¡¡¡¡
2 HDAC3ÓëѪ¹ÜÄÚÆ¤Ï¸°û
¡¡¡¡
¡¡¡¡2.1 HDAC3Ó°ÏìÖ×ÁöѪ¹ÜÉú³É
¡¡¡¡
¡¡¡¡HDAC3Ϊ¢ñÀàHDACs, ËüÄܹ»Í¨¹ýË®½â×éµ°°×ÖеÄÒÒõ£»ùÍÅ´Ó¶øÒÖÖÆ»ùÒòת¼£¬ ÇÒHDAC3ÐèÓëÌåÄ򵀮äÓ൰°×ÁªºÏÐγɸ´ºÏÎï´Ó¶ø·¢»ÓÉúÀí»îÐÔ¡£½áºÏµÄµ°°×Ö÷ÒªÓм××´ÏÙËØÊÜÌå³ÁĬµ÷½Ú×ÓºÍά¼×ËáÊÜÌ弰ϸ°ûºËÐͬÊÜÌåµÈ¡£MANIOTISµÈÔÚÑо¿Ñª¹ÜÄÚÆ¤Ï¸°ûÒò×Ó»úÖÆµÄ¹ý³ÌÖÐÀûÓÃPAS-CD34Ë«ÖØ¶Ô±ÈȾɫ·¨£¬ ¾¹ý¶ÔȾɫ³É¹ûºÍÁÙ´²Êý¾ÝÆÊÎöµÃϤ£ºHDAC3µÄ±í´ï³Ì¶ÈºÍ½ºÖÊÁö·Ö¼¶ÓйØÏµ[1,6-7].Ŀǰ·üÁ¢ÅµËû £¨vorinostat£© ¡¢Çú¹ÅÃ¹ËØA¡¢FK228¡¢LAQ824ºÍ¶¡ËáÑÎÄܹ»ÒÖÖÆÖ×ÁöѪ¹ÜÉú³É[8], Æä»úÖÆÖ÷ÒªÊÇͨ¹ý½µµÍµÍÑõÓÕµ¼Òò×Ó-1αºÍѪ¹ÜÄÚÆ¤Éú³¤Òò×Ó £¨vascular endothelial growth factor, VEGF£© µÄ±í´ï¡£È»¶ø£¬ HDAC3¿ÉÒÔͨ¹ý½µµÍp53»ùÒòºÍp VHLµÄ±í´ï£¬ ´ïµ½´Ù½øµÍÑõÓÕµ¼Òò×Ó-1αµÄ±í´ï²¢´Ù½øÑª¹ÜµÄÐγÉЧ¹û¡£¿É¼ûHDAC3ÓëÖ×ÁöѪ¹ÜÉú³ÉÓÐÒ»¶¨¹ØÏµ¡£ÊµÑé·¢ÏÖÔÚÉñ¾½ºÖÊÁöÖÐ×éµ°°×È¥ÒÒõ£»¯Ã¸±í´ï¹ýÁ¿HDACs¶ÔÉñ¾½ºÖÊÁöÒ²ÓÐÒ»¶¨µÄ×÷ÓÃ[9].
¡¡¡¡
¡¡¡¡2.2 HDAC3ÓëÄÚÆ¤Ï¸°ûÔöÖ³¡¢µòÍöºÍ·Ö»¯
¡¡¡¡
¡¡¡¡ÔÚÉúÀíÇé¿öÏ£¬ Ѫ¹Ü±ÚÄÚÆ¤´¦ÓÚ¾²Ö¹µÄ״̬¡£µ±Ñª¹ÜÊܵ½½á¹¹»ò¹¦ÄÜÆÆ»µÊ±ÄÚÆ¤Ï¸°û¾Í»á´óÁ¿ÔöÖ³¡£ÓÐÑо¿·¢ÏÖ£ºHDAC3ÓëѪ¹ÜÄÚÆ¤Ï¸°ûµÄÔöÖ³Óйء£HDACs±¾Éí×÷ΪºËСÌåµÄÖØÒª×é³É²¿·Ö£¬ ¿ÉÒÔÖ±½Ó²ÎÓëϸ°ûÖÜÆÚµÄµ÷¿Ø[5].LEEµÈ[10]·¢ÏÖ£¬ ÊÊÓ¦µÄ¼ôÇÐÁ¦Äܹ»²Ù×ÝÁ×Ëáõ¥¼¡´¼3-¼¤Ã¸/Ë¿°±Ëá/ËÕ°±Ëáµ°°×¼¤Ã¸ £¨phosphatidylinositol 3-kinase, PI3K/Akt£© ;¾¶Éϵ÷HDAC3¡¢Ï¸°ûÖÜÆÚËØA, ͬʱϵ÷ϸ°ûÖÜÆÚ¸ºµ÷¿Øµ°°×P21, ½á¹û±íÃ÷HDAC3¿ÉÒÔ´Ù½øÄÚÆ¤Ï¸°ûµÄÔöÖ³¡£MTTºÍTranswellʵÑé½á¹ûÒ²ÏÔʾ£ºHDAC3ȷʵӰÏìϸ°ûµÄÔöֳϮÐÔ[7], µ«HDAC3ÓëÄÚÆ¤Ï¸°ûŨ¶ÈÔö³¤ÇúÏß»¹²»Ã÷È·¡£
¡¡¡¡
¡¡¡¡HDAC3¶ÔÄÚÆ¤Ï¸°ûµÄµòÍöºÍÉú´æ¶¼Æð×ŷdz£ÖØÒªµÄ×÷Óá£Ï¸°ûµòÍöÊÇÓÉϸ°ûÓÚÌØÒìÐԴ̼¤ºó£¬ ¾Í»áÆô¶¯Ï¸°ûÄÚÔÚµÄ×ÔɱÒò×ÓËùµ¼ÖµÄÒ»ÖÖ³ÌÐòÐÔϸ°ûËÀÍö¡£ÔÚHDAC3µÄÑо¿¹ý³ÌÖз¢ÏÖ£¬ LBH589ºÍKD7150 £¨HDACÒÖÖÆ¼Á£© ÔÚϸ°ûˮƽºÍ¶¯ÎïʵÑéÖж¼¿ÉÒÔÆðµ½ÓÕ·¢DNAËðÉË£¬ Ìá¸ß»îÐÔÑõˮƽ£¬ ÒÖÖÆ°×Ѫ²¡Ï¸°ûÔöÖ³£¬ ´Ù½øÏ¸°ûµòÍöµÄ×÷ÓÃ[11].¸ÃÑо¿³õ²½Ö¤ÊµHDAC3Äܹ»´ÙʹѪ¹ÜÄÚÆ¤Ï¸°ûµÄµòÍö¡£´ËÍ⣬ HDAC3Äܹ»¾¹ý¼¤»îAkt1ʹµÃѪ¹Ü´¦ÓÚÒ»ÖÖ¹®¹Ì״̬£¬ Ò²¿ÉÒÔͨ¹ý¸Ð֪Ѫ¹Ü±Ú»úеÁ¦µÄ±ä»¯±£»¤Ñª¹ÜÄÚÆ¤[12], ¹²Í¬´ïµ½Ê¹ÄÚÆ¤Ï¸°ûÎȶ¨´æ»îЧ¹û¡£
¡¡¡¡
¡¡¡¡HDAC3²»½öÄÜ´Ù½øÄÚÆ¤Ï¸°ûµÄÉú´æ£¬ »¹²ÎÓë¸É×æÏ¸°ûÏòÄÚÆ¤Ï¸°û·Ö»¯¡£ÉúÎï¹È±¨µÀ£ºÎÒÃÇÒѾ֪µÀÌØ¶¨µÄ²ãÁ÷¼ôÇÐÓ¦Á¦»òÕßVEGF¾ù±»Ö¤Êµ¿ÉÒÔ´Ù½øÅßÌ¥¸Éϸ°ûºÍ×æÏ¸°ûÏòÄÚÆ¤Ï¸°û·Ö»¯[13].»ªÈËѧÕßÐìÇ岨Ñо¿·¢ÏÖ£ºFIk-1-PI3K-Akt-HDAC3-p53-p21ͨ·ÔÚÆäÖаçÑÝןËÐÄ×÷Ó㬠´Ëͨ·Ϊ¶¨Ïò¿ØÖÆÅßÌ¥¸Éϸ°û·Ö»¯Ìá¹©ÖØÒªÀíÂÛ»ù´¡¡£Ñо¿·¢ÏÖHDAC3ÄÜ´Ù½øÄÚÆ¤Ï¸°ûµÄÔöÖ³£¬ ²¢Ö¤ÊµHDAC3øÒÖÖÆ¼Á¿ÉÓÃÓÚÒÖÖÆ½ºÖÊÁöϸ°ûµÄÔöÖ³[14].
¡¡¡¡
¡¡¡¡2.3 HDAC3ÒÖÖÆ¼Á
¡¡¡¡
¡¡¡¡HDACsÒÖÖÆ¼Á¿ÉÒÔͨ¹ýÈÅÂÒHDACs¹¦Ð§¶ø´ïµ½ÖÎÁÆÑª¹Ü¼²²¡µÄÄ¿µÄ¡£HDACsÒÖÖÆ¼ÁÖÐÖ÷ÒªÕë¶ÔHDAC3µÄÒÖÖÆ¼ÁÓÐ4ÖÖ£¬ °üÀ¨ÒìôÇë¿Ëá¡¢¶ÌÁ´Ö¬·¾Ëá¡¢»·ÐÎËÄëĺͱ½Ëá°·¡£
¡¡¡¡
¡¡¡¡HDAC3ÒÖÖÆ¼Á¿ÉÒÔÒÖÖÆÑª¹ÜÄÚÆ¤Ï¸°ûµÄÔöÖ³£¬ ´Ù½øÄÚÆ¤Ï¸°ûµÄµòÍö¡£ÒìôÇë¿ËáÀàÒÖÖÆ¼ÁÊÇĿǰ·¢ÏÖ×îÔç¡¢·Ö²¼×î¹ã·ºµÄÒ»ÀàHDAC3ÒÖÖÆ¼Á£¬ ËüÖ÷Òª×÷ÓÃÓÚ¢ñºÍ¢òÀàHDACs.ÒÑÓÐÑо¿±íÃ÷£¬ ÔÚÊæÕŵÄѪ¹ÜºÍÐÂÉúѪ¹ÜÐγɹý³ÌÖУ¬ HDACsͨ¹ýϵ÷ÄÚÆ¤ÐÍÒ»Ñõ»¯µªºÏøµÄ±í´ï£¬ µ÷½ÚÄÚÆ¤Ï¸°û¹¦ÄÜ[15-16].¶ÌÁ´Ö¬·¾ËáÀàÒÖÖÆ¼ÁÖ÷Òª°üÀ¨±ûÎìËá¡¢±½¶¡ËáºÍÕý¶¡Ëá¼°ÆäÑÎÀ໯ºÏÎ Ö÷ҪΪHDAC¢ñºÍHDAC¢òa²úÉú×÷Ó㬠¶ÔHDAC¢òbÔòÎÞÓ°Ïì¡£ÓÉÓÚ¶ÌÁ´Ö¬·¾Ëá¿ÉÒÔÓÐЧÒÖÖÆHDACsµÄ×÷ÓúÍÐÂÉúѪ¹ÜµÄÐγɣ¬ Òò´ËËü¿ÉÊÔÓÃÓÚÖ×Áö¼²²¡µÄÖÎÁÆ¡£ÓÐÑо¿Õß¶Ô±ûÎìËáÖÎÁƸßѪѹ´óÊó½øÐÐÑо¿£¬ Æä½á¹û±íÃ÷£º¾±ûÎìËáÖÎÁƵĸßѪѹ´óÊóµÄ×óÐÄÊҷʺñµÃµ½Ã÷ÏÔÄæ×ª[17].±ûÎìËáÒѱ»±¨µÀÔÚÌåÄÚºÍÌåÍâÒÖÖÆ»îÌåÄÚÍâÐÂÉúѪ¹ÜµÄÐγɡ£±ûÎìËá¸ÉÔ¤µÄÀÏÊóÅß̥ʵÑé½á¹ûÒ²ÏÔʾÆä¿ÉÒÔ·Á°Âö¹ÜµÄÐγɣ¬ ÒÔ¼°ÏÞÖÆÉÏÆ¤Ï¸°ûµÄÔöÖ³¡¢Ç¨ÒƺÍëϸѪ¹ÜµÄÐγÉ[18].»·ÐÎËÄëÄÀàÒÖÖÆ¼Áº¬ÓÐtrapoxin¡¢apicidin¡¢HC-toxinºÍFK228µÈ£¬ Ö÷Òª×÷ÓÃÓÚ¢ñÐÍHDACs.ÕâЩ»¯ºÏÎﺬÓÐÒ»¸ö»·ËÄëĽṹ¡£±½°·ËáÀàÒÖÖÆ¼ÁµÄÖ÷Òª×÷ÓðеãÊÇ¢ñÐÍHDACs, ´ËÀàÒÖÖÆ¼ÁÖ÷Òª°üÀ¨MS-275¡¢SNDX-275ºÍMGCDO101µÈ£¬ ÆäÖÐMS-275µÄÑ¡ÔñÐÔÇ¿£¬ ¶¾ÐԵͣ¬ ¿¹Ö×Áö»îÐÔÏÔ×Å¡£
¡¡¡¡
¡¡¡¡ÓÐÑо¿·¢ÏÖ£ºHDAC3ÒÖÖÆ¼ÁÓëÖÎÁÆÌÇÄò²¡ÊÓÍøÄ¤²¡ÓÐÃÜÇйØÏµ¡£HDAC3ÒÖÖÆ¼Áͨ¹ý¼õÈõHDAC3¶ÔѪ¹ÜÄÚÆ¤Ï¸°û×÷Ó㬠ÒÖÖÆÌÇÄò²¡ÊÓÍøÄ¤²¡±äÐÂÉúѪ¹ÜµÄÐγÉ[19].ºÏÊʵÄHDAC3ÒÖÖÆ¼Á¿ÉÒÔÓÐЧÏÞÖÆÄÚÆ¤Ï¸°ûµÄ¹¦ÄÜ¡£ÆäÐë¾ßÓÐ3ÖÖÌØµã£º £¨1£© ¼õÈõHDAC3µÄ¹¦ÄÜ£» £¨2£© ÒÖÖÆHDACsµÄ»ùÒòת¼¹ý³Ì£» £¨3£© Ôö¼Ó×éµ°°×ÒÒõ£×ªÒÆÃ¸ÓëÄ¿±ê»ùÒòµÄÆô¶¯×ӵĽáºÏÂÊ[20].³ý´ËÖ®Í⣬ HDAC3ÒÖÖÆ¼ÁÓëÖÎÁÆÐÄѪ¹Ü¼²²¡Ò²Óйأ¬ µ«Æä»úÖÆÒÔ¼°ÆäÓëѪ¹ÜÄÚÆ¤Ï¸°ûµÄ¹ØÏµÈÔÐèÒª½øÒ»²½Ñо¿¡£
¡¡¡¡
¡¡¡¡×ÛÉÏËùÊö£¬ HDACsÓÈÆäÊÇHDAC3ÓëѪ¹ÜÄÚÆ¤Ï¸°ûµÄ¹ØÏµ¼«ÎªÃÜÇС£HDAC3Ó°ÏìѪ¹ÜÄÚÆ¤Ï¸°ûµÄÔöÖ³¡¢·Ö»¯ÓëµòÍö£¬ ¼Ì¶øÓ°ÏìѪ¹ÜµÄÉú³É¡£Ä¿Ç°ÒÑ·¢ÏÖµÄ4ÖÖHDAC3ÒÖÖÆ¼ÁҲͨ¹ýµ÷¿ØÄÚÆ¤Ï¸°ûÀ´Ó°ÏìѪ¹ÜµÄÉú³É£¬ ´Ó¶ø¸üºÃÖÎÁÆÌÇÄò²¡ÊÓÍøÄ¤²¡¡£ÎªÁËÖÎÁƸ÷ÖÖÐÄѪ¹Ü¼²²¡¡¢·¢ÏÖ¸üºÃµÄHDACSÒÖÖÆ¼Á£¬ ÐèÒª¸ü¼ÓÉîÈëµØÑо¿HDAC3¼°ÆäËûHDACS²¡ÀíÉúÀíѧ·½ÃæµÄÏ໥×÷Óü°»úÖÆ¡£
¡¡¡¡
¡¡¡¡²Î¿¼ÎÄÏ×
¡¡¡¡
¡¡¡¡[1]GLOZAK M A, SETO E.Histone deacetylases and cancer[J].Oncogene, 2007, 26 £¨37£© :5420-5432.¡¡¡¡
¡¡¡¡[2]TANG J H, YAN H D, ZHUANG S G.Histone deacetylases as targets for treatment of multiple diseases[J].Clin Sci £¨Lond£© , 2013, 124 £¨11£© :651-662.¡¡¡¡
¡¡¡¡[3]NATHAN C.Points of control in inflammation[J].Nature, 2002, 420 £¨6917£© :846-852.
¡¡¡¡[4]VERDIN E, DEQUIEDT F, KASLER H G.Class¢òhistone deacetylases:versatile regulators[J].Trends Genet, 2003, 19 £¨5£© :286-293.¡¡¡¡
¡¡¡¡[5]Ñî¿¡Ñþ£¬ Íõǰ£¬ ZENG L F.×éµ°°×È¥ÒÒõ£»¯Ã¸ÓëѪ¹ÜÖØ½¨[J].Öлª¸ßѪѹÔÓÖ¾£¬ 2014, 22 £¨5£© :403-409.¡¡¡¡
¡¡¡¡[6]ZHU J, WAN H, XUE C Q, et al.Histone deacetylase3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration[J].Brain Res, 2013, 1520:15-22.¡¡¡¡
¡¡¡¡[7]SEFTOR R E, SEFTOR E A, KOSHIKAWA N, et al.Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma[J].Cancer Res, 2001, 61 £¨17£© :6322-6327.¡¡¡¡
¡¡¡¡[8]LIANG D M, KONG X G, SANG N L.Effects of histone deacetylase inhibitors on HIF-1[J].Cell Cycle, 2006, 5 £¨21£© :2430-2435.¡¡¡¡
¡¡¡¡[9]Àî»Ý³¿£¬ ÂíÓÂÕþ£¬ ÉêÁÁÁÁ£¬ µÈ¡£µ°°×ÖÊÒÒõ£»¯ÐÞÊÎÔÚÖ×Áö·¢Éú¡¢ÖÎÁÆÖеÄ×÷ÓÃÑо¿½øÕ¹[J].ɽ¶«Ò½Ñ§£¬ 2014, 54 £¨27£© :89-92.¡¡¡¡
¡¡¡¡[10]LEE D Y, LEE C I, LIN T E, et al.Role of histone deacetylases in transcription factor regulation and cell cycle modulation in endothelial cells in response to disturbed flow[J].Proc Natl Acad Sci U S A, 2012, 109 £¨6£© :1976-1972.¡¡¡¡
¡¡¡¡[11]SCUTO A, KIRSCHBAUM M, KOWOLIK C, et al.The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Phacute lymphoblastic leukemia cells[J].Blood, 2008, 111 £¨10£© :5093-5100.¡¡¡¡
¡¡¡¡[12]ZAMPETAKI A, ZENG L F, MARGARITI A, et al.Histone deacetylase 3 is critical in endothelial survival and atherosclerosis development in response to disturbed flow[J].Circulation, 2010, 121 £¨1£© :132-142.¡¡¡¡
¡¡¡¡[13]ZENG L F, XIAO Q Z, MARGARITI A, et al.HDAC3 is crucial in shear-and VEGF-induced stem cell differentiation toward endothelial cells[J].J Cell Biol, 2006, 174 £¨4£© :1059-1069.¡¡¡¡
¡¡¡¡[14]LIB¦eP, KOSTROUCHOV¦BM, POHLUDKA M, et al.Elevated and deregulated expression of HDAC3 in human astrocytic glial tumours[J].Folia Biol £¨Praha£© , 2006, 52 £¨1/2£© :21-33
¡¡¡¡[15]IGNARRO L J, BUGA G M, WOOD K S, et al.Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide[J].Proc Natl Acad Sci U S A, 1987, 84 £¨24£© :9265-9269.¡¡¡¡
¡¡¡¡[16]WANG Y S, CHEN T, YAN H J, et al.Role of histone deacetylase inhibitors in the aging of human umbilical cordmesenchymal stem cells[J].J Cell Biochem, 2013, 114 £¨10£© :2231-2239.¡¡¡¡
¡¡¡¡[17]BERMDEZ-LUGO J A, PEREZ-GONZALEZ O, ROSALES-HERN¦BNDEZ M C, et al.Exploration of the valproic acid binding site on histone deacetylase 8 using docking and molecular dynamic simulations[J].J Mol Model, 2011, 18 £¨6£© :2301-2310.¡¡¡¡
¡¡¡¡[18]MICHAELIS M, MICHAELIS U R, FLEMING I, et al.Valproic acid inhibits angiogenesis in vitro and in vivo[J].Mol Pharmacol, 2004, 65 £¨3£© :520-527.¡¡¡¡
¡¡¡¡[19]л°²Ã÷£¬ ÍõÑžý£¬ ´ÞÀö¬B¡£Ñª¹ÜÄÚÆ¤×æÏ¸°ûÓëVEGF¶ÔÔöÉúÐÔÌÇÄò²¡ÊÓÍøÄ¤²¡±äÐÂÉúѪ¹ÜÐγɵÄÓ°Ïì[J].Î÷°²½»Í¨´óѧѧ±¨ £¨Ò½Ñ§°æ£© , 2013, 34 £¨2£© :233-236.¡¡¡¡
¡¡¡¡[20]ÍõÐÀ£¬ Áõµ¤£¬ ÂÀ½ðÁᣬ µÈ¡£×éµ°°×È¥ÒÒõ£Ã¸ÒÖÖÆ¼ÁµÄÑо¿½øÕ¹[J].ÖйúÒ©ÎﻯѧÔÓÖ¾£¬ 2006, 16 £¨5£© :316-322.